Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Liabilities and Shareholders Equity: 2022-2025

Historic Liabilities and Shareholders Equity for Immunocore Holdings (IMCR) over the last 2 years, with Sep 2025 value amounting to $1.1 billion.

  • Immunocore Holdings' Liabilities and Shareholders Equity rose 1.65% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 14.15%. This contributed to the annual value of $1.0 billion for FY2024, which is 69.10% up from last year.
  • Latest data reveals that Immunocore Holdings reported Liabilities and Shareholders Equity of $1.1 billion as of Q3 2025, which was up 1.86% from $1.1 billion recorded in Q2 2025.
  • Over the past 5 years, Immunocore Holdings' Liabilities and Shareholders Equity peaked at $1.1 billion during Q3 2025, and registered a low of $526.8 million during Q4 2022.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $1.0 billion (2024), whereas its average is $990.2 million.
  • Data for Immunocore Holdings' Liabilities and Shareholders Equity shows a peak YoY spiked of 69.10% (in 2024) over the last 5 years.
  • Over the past 4 years, Immunocore Holdings' Liabilities and Shareholders Equity (Quarterly) stood at $526.8 million in 2022, then grew by 13.33% to $597.0 million in 2023, then skyrocketed by 69.10% to $1.0 billion in 2024, then climbed by 1.65% to $1.1 billion in 2025.
  • Its Liabilities and Shareholders Equity was $1.1 billion in Q3 2025, compared to $1.1 billion in Q2 2025 and $1.0 billion in Q1 2025.